Oxybutynin Chloride

CHEMBL1133 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

393.9 g/mol

LogP

—

Phase

4

A chloride form of oxybutynin with the same therapeutic properties. An anticholinergic treating overactive bladder symptoms and bladder dysfunction in multiple sclerosis.

分子量

393.9000 g/mol

TPSA

49.80 Å²

治療領域

Parkinson's Disease Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Multiple Sclerosis Breast Cancer Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1.Cl

InChI

InChI=1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H

Molecular Formula

C22H32ClNO3

HBD / HBA

2 / 4

回転可能結合数

8

重原子数

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A chloride form of oxybutynin with the same therapeutic properties. An anticholinergic treating overactive bladder symptoms and bladder dysfunction in multiple sclerosis.

Yes, Oxybutynin Chloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1133. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 91505. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Oxybutynin Chloride PillFYIで

構造

クイックデータ

分子式: C22H32ClNO3
同義語: 3

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.